Study of Breast Cancer Drug Halted After Causing Deaths
Posted on: Wednesday, 18 May 2005, 09:00 CDT
Study of breast cancer drug halted after causing deaths
WASHINGTON, May 17 (Xinhua) -- A study to test a combination of two chemotherapy drugs in treating breast cancer was halted after leading to the death of two patients, French researchers reported on Tuesday.
The tested medication were standard intravenous drug doxorubicin plus a newer drug called docetaxel. Researchers want to see if combining the two frequently used breast cancer drugs can have better effects as shown by previous similar tries, according to the researchers who wrote in this week's Journal of the American Medical Association.
The combination, which was too toxic, can increase risk of severe and life-threatening complications, concluded the researchers from the Huguenin Cancer Center, Saint-Cloud, France.
The report said 627 women ages 18 to 70 participated in the study aimed to prolong their life for at least five years. All of the participants had a high risk of cancer recurrence.
The study was halted about three years after it started in 1999, because of the subsequent two deaths and a high rate of complications including low white-cell counts with fever, which is a life-threatening condition coming as a result of weakened body's ability to fight infection.
Source: Xinhua News Agency - CEIS
Related Articles
- A&G Receives $870,000 Grant From Avon for Breast Cancer Studies
- Breast Cancer Study
- US Oncology Research Network Presenting Numerous Studies at San Antonio Breast Cancer Symposium
- No link between statins and breast cancer: study
- Ulster Breast Cancer Patient in Battle for Wonder Drug
- Tai Chi Helps Women Recover From Breast Cancer Surgery: Researcher
- Study Subjects Protest Halt to Drug That Helps
- Study Shows Adolescence Affects Breast Cancer
- New Study Links Antibiotics and Breast Cancer
- Study Links Antibiotics and Breast Cancer
 |
 |
User Comments (0)
RSS Feeds